Fardel O - Search Results

1

Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes.

Fardel O, Moreau A, Le Vée M, Denizot C, Parmentier Y. Fardel O, et al. Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):13-30. doi: 10.1007/s13318-018-0502-x. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30167999 Review.

2

Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons.

Vernhet L, Allain N, Le Vée M, Morel F, Guillouzo A, Fardel O. Vernhet L, et al. Among authors: fardel o. J Pharmacol Exp Ther. 2003 Jan;304(1):145-55. doi: 10.1124/jpet.102.042176. J Pharmacol Exp Ther. 2003. PMID: 12490585

3

[Drug membrane transporters in the liver: regulation of their expression and activity].

Fardel O, Payen L, Sparfel L, Vernhet L, Lecureur V. Fardel O, et al. Ann Pharm Fr. 2002 Nov;60(6):380-5. Ann Pharm Fr. 2002. PMID: 12514503 French.

4

Polycyclic aromatic hydrocarbons inhibit differentiation of human monocytes into macrophages.

van Grevenynghe J, Rion S, Le Ferrec E, Le Vee M, Amiot L, Fauchet R, Fardel O. van Grevenynghe J, et al. Among authors: fardel o. J Immunol. 2003 Mar 1;170(5):2374-81. doi: 10.4049/jimmunol.170.5.2374. J Immunol. 2003. PMID: 12594260

5

Cytochrome P450-dependent toxicity of environmental polycyclic aromatic hydrocarbons towards human macrophages.

van Grevenynghe J, Sparfel L, Le Vee M, Gilot D, Drenou B, Fauchet R, Fardel O. van Grevenynghe J, et al. Among authors: fardel o. Biochem Biophys Res Commun. 2004 May 7;317(3):708-16. doi: 10.1016/j.bbrc.2004.03.104. Biochem Biophys Res Commun. 2004. PMID: 15081398

6

Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives.

Sparfel L, Huc L, Le Vee M, Desille M, Lagadic-Gossmann D, Fardel O. Sparfel L, et al. Among authors: fardel o. Biochem Pharmacol. 2004 May 1;67(9):1711-9. doi: 10.1016/j.bcp.2004.01.005. Biochem Pharmacol. 2004. PMID: 15081870

7

Physiological, pharmacological and clinical features of the multidrug resistance protein 2.

Fardel O, Jigorel E, Le Vee M, Payen L. Fardel O, et al. Biomed Pharmacother. 2005 Apr;59(3):104-14. doi: 10.1016/j.biopha.2005.01.005. Biomed Pharmacother. 2005. PMID: 15795103 Review.

8

Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes.

Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, Fardel O. Jigorel E, et al. Among authors: fardel o. Drug Metab Dispos. 2005 Oct;33(10):1418-22. doi: 10.1124/dmd.105.004762. Epub 2005 Jul 13. Drug Metab Dispos. 2005. PMID: 16014767

9

Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin alpha.

Sparfel L, Van Grevenynghe J, Le Vee M, Aninat C, Fardel O. Sparfel L, et al. Among authors: fardel o. Carcinogenesis. 2006 Mar;27(3):656-63. doi: 10.1093/carcin/bgi256. Epub 2005 Oct 29. Carcinogenesis. 2006. PMID: 16258175

10

Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.

Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Le Vee M, et al. Among authors: fardel o. Eur J Pharm Sci. 2006 May;28(1-2):109-17. doi: 10.1016/j.ejps.2006.01.004. Epub 2006 Feb 20. Eur J Pharm Sci. 2006. PMID: 16488578

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters